Adjuvant therapy
SABCS 2019: Cyclin E Expression
AUTHORS: Lorenza Mittempergher, Joseph McKelley, Rajith Bhaskaran, Sahra Uygun, Reneฬ Read More
SABCS 2019: PROMIS Clinical Risk
AUTHORS: Michaela Tsai, Hatem Soliman, Shelly Lo, Rubina Qamar, Raye Read More
Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial
PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline GalleryRole of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
PUBLICATION: Journal of Clinical Oncology 37, no. 22 (August 01, Read More
The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer
PUBLICATION: Ann Surg Oncol (2019) 26: 3495. https://doi.org/10.1245/s10434-019-07511-8. AUTHORS: J.E.C. Read More
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More
Association of 70-Gene Signature Assay Findings With Physiciansโ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay GalleryAssociation of 70-Gene Signature Assay Findings With Physiciansโ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Association of 70-Gene Signature Assay Findings With Physiciansโ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Read More
- Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen ReceptorโPositive Early Breast Cancer: Results of a Prospective Cohort Study Gallery
Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen ReceptorโPositive Early Breast Cancer: Results of a Prospective Cohort Study
Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen ReceptorโPositive Early Breast Cancer: Results of a Prospective Cohort Study
PUBLICATION: Journal of Clinical Oncology 35, no. 24 (August 20, Read More
- Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial. Gallery
Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.
Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.
PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages Read More
A Breast Cancer Gene Signature for Indolent Disease
PUBLICATION: Breast Cancer Res Treat. 2017 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub Read More
